The renal denervation devices market size has grown exponentially in recent years. It will grow from $0.74 billion in 2025 to $0.98 billion in 2026 at a compound annual growth rate (CAGR) of 32.5%. The growth in the historic period can be attributed to rising prevalence of resistant hypertension, advancements in catheter ablation technologies, increasing clinical research in renal denervation, expansion of interventional cardiology procedures, growing awareness of non-pharmacological hypertension treatments.
The renal denervation devices market size is expected to see exponential growth in the next few years. It will grow to $3.01 billion in 2030 at a compound annual growth rate (CAGR) of 32.4%. The growth in the forecast period can be attributed to increasing regulatory approvals for renal denervation devices, rising adoption in outpatient settings, growing demand for long-term hypertension management solutions, expansion of clinical evidence supporting efficacy, increasing investment in next-generation ablation systems. Major trends in the forecast period include increasing adoption of catheter-based hypertension therapies, growing use of radiofrequency and ultrasound ablation technologies, rising focus on minimally invasive cardiovascular interventions, expansion of image-guided renal denervation procedures, enhanced emphasis on procedure safety and precision.
The increasing prevalence of hypertension is expected to drive the growth of the renal denervation devices market. Hypertension, or high blood pressure, is a condition in which the force of blood against the walls of blood vessels remains consistently elevated. Renal denervation is a catheter-based, minimally invasive procedure developed as a potential treatment for patients with resistant hypertension that does not respond adequately to medication. For instance, in January 2025, according to the Centers for Disease Control and Prevention, a US-based government agency, high blood pressure contributed to or directly caused 664,470 deaths in the United States in 2023. Therefore, the rising prevalence of hypertension is promoting demand for renal denervation devices.
Leading companies in the renal denervation devices market are concentrating on the development of ultrasound renal denervation (uRDN) to improve treatment effectiveness, minimize procedural complications, and offer a non-invasive alternative to conventional renal denervation methods. uRDN enhances renal denervation devices by facilitating precise, non-invasive energy delivery to the renal nerves, which effectively reduces blood pressure while safeguarding surrounding tissues, thereby increasing patient safety and comfort during the procedure. For example, in November 2023, Recor Medical Inc., a US-based medical technology firm, introduced the Paradise uRDN system, an innovative ultrasound renal denervation device aimed at treating hypertension in patients who have not reached blood pressure targets through standard lifestyle modifications and medications. This system incorporates hydrocooling technology to protect the renal artery during the procedure, marking a significant advancement in the renal denervation devices market by providing a novel, non-pharmacologic method for managing resistant hypertension and broadening treatment options for patients.
In May 2025, Boston Scientific Corporation, a US-based biotechnology and biomedical engineering firm, acquired SoniVie Ltd. for $360 million. Through this acquisition, Boston Scientific aims to expand its interventional cardiology portfolio by integrating SoniVie’s TIVUS intravascular ultrasound system, an investigational device designed for renal artery denervation in hypertension treatment. SoniVie Ltd. is an Israel-based manufacturer specializing in renal denervation devices.
Major companies operating in the renal denervation devices market are Medtronic PLC, ReCor Medical Inc., Boston Scientific Corporation, Abbott Laboratories, Cordis Corporation, Terumo Corporation, Kona Medical Inc., St. Jude Medical LLC, Johnson & Johnson, Symple Surgical Inc., Cardiosonic Ltd., Mercator MedSystems Inc., Ablative Solutions Inc., Renal Dynamics Ltd., Vesalio LLC, Biotronik SE & Co. KG, Cook Medical LLC, Hansen Medical Inc., Merit Medical Systems Inc., AngioDynamics Inc., Covidien Ltd., Volcano Corporation.
Europe was the largest region in the renal denervation devices market in 2025.Asia-Pacific is expected to be the fastest-growing region in the global renal denervation devices market report during the forecast period. The regions covered in the renal denervation devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the renal denervation devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the renal denervation devices market by increasing costs of imported catheters, generators, ablation components, imaging accessories, and precision electronic parts used in minimally invasive systems. Hospitals and cardiovascular centers in North America and Europe are most affected due to dependence on imported medical devices, while Asia-Pacific faces pricing pressure on advanced interventional equipment. These tariffs are raising procedure costs and influencing procurement decisions. However, they are also encouraging localized manufacturing, regional supplier partnerships, and greater investment in domestic production of cardiovascular intervention devices.
The renal denervation devices market research report is one of a series of new reports that provides renal denervation devices market statistics, including renal denervation devices industry global market size, regional shares, competitors with a renal denervation devices market share, detailed renal denervation devices market segments, market trends and opportunities, and any further data you may need to thrive in the renal denervation devices industry. This renal denervation devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Renal denervation devices represent minimally invasive medical solutions designed for the treatment of resistant hypertension cases unresponsive to conventional interventions. These devices involve the insertion of a catheter into the renal arteries, employing radiofrequency energy to ablate sympathetic nerves within the vessel walls. This process enhances blood flow to the kidneys.
Key products in the renal denervation devices market include the Simplicity Renal Denervation System, EnligHTN, Vessix Renal Denervation System, Iberis Renal Sympathetic Denervation System, Paradise Renal Denervation System, and others. The Simplicity Renal Denervation System, for instance, utilizes a catheter and generator to deliver radiofrequency energy to the renal nerves. Various technologies, such as radiofrequency ablation, ultrasound energy-based RDN, brachytherapy, chemical ablation, and others, are employed by these devices. Target end-users include hospitals, cardiovascular research centers, and other medical facilities.
The renal denervation devices market consists of sales of products including a single electrode, multi-electrode, irrigated catheter, and others. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The renal denervation devices market size is expected to see exponential growth in the next few years. It will grow to $3.01 billion in 2030 at a compound annual growth rate (CAGR) of 32.4%. The growth in the forecast period can be attributed to increasing regulatory approvals for renal denervation devices, rising adoption in outpatient settings, growing demand for long-term hypertension management solutions, expansion of clinical evidence supporting efficacy, increasing investment in next-generation ablation systems. Major trends in the forecast period include increasing adoption of catheter-based hypertension therapies, growing use of radiofrequency and ultrasound ablation technologies, rising focus on minimally invasive cardiovascular interventions, expansion of image-guided renal denervation procedures, enhanced emphasis on procedure safety and precision.
The increasing prevalence of hypertension is expected to drive the growth of the renal denervation devices market. Hypertension, or high blood pressure, is a condition in which the force of blood against the walls of blood vessels remains consistently elevated. Renal denervation is a catheter-based, minimally invasive procedure developed as a potential treatment for patients with resistant hypertension that does not respond adequately to medication. For instance, in January 2025, according to the Centers for Disease Control and Prevention, a US-based government agency, high blood pressure contributed to or directly caused 664,470 deaths in the United States in 2023. Therefore, the rising prevalence of hypertension is promoting demand for renal denervation devices.
Leading companies in the renal denervation devices market are concentrating on the development of ultrasound renal denervation (uRDN) to improve treatment effectiveness, minimize procedural complications, and offer a non-invasive alternative to conventional renal denervation methods. uRDN enhances renal denervation devices by facilitating precise, non-invasive energy delivery to the renal nerves, which effectively reduces blood pressure while safeguarding surrounding tissues, thereby increasing patient safety and comfort during the procedure. For example, in November 2023, Recor Medical Inc., a US-based medical technology firm, introduced the Paradise uRDN system, an innovative ultrasound renal denervation device aimed at treating hypertension in patients who have not reached blood pressure targets through standard lifestyle modifications and medications. This system incorporates hydrocooling technology to protect the renal artery during the procedure, marking a significant advancement in the renal denervation devices market by providing a novel, non-pharmacologic method for managing resistant hypertension and broadening treatment options for patients.
In May 2025, Boston Scientific Corporation, a US-based biotechnology and biomedical engineering firm, acquired SoniVie Ltd. for $360 million. Through this acquisition, Boston Scientific aims to expand its interventional cardiology portfolio by integrating SoniVie’s TIVUS intravascular ultrasound system, an investigational device designed for renal artery denervation in hypertension treatment. SoniVie Ltd. is an Israel-based manufacturer specializing in renal denervation devices.
Major companies operating in the renal denervation devices market are Medtronic PLC, ReCor Medical Inc., Boston Scientific Corporation, Abbott Laboratories, Cordis Corporation, Terumo Corporation, Kona Medical Inc., St. Jude Medical LLC, Johnson & Johnson, Symple Surgical Inc., Cardiosonic Ltd., Mercator MedSystems Inc., Ablative Solutions Inc., Renal Dynamics Ltd., Vesalio LLC, Biotronik SE & Co. KG, Cook Medical LLC, Hansen Medical Inc., Merit Medical Systems Inc., AngioDynamics Inc., Covidien Ltd., Volcano Corporation.
Europe was the largest region in the renal denervation devices market in 2025.Asia-Pacific is expected to be the fastest-growing region in the global renal denervation devices market report during the forecast period. The regions covered in the renal denervation devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the renal denervation devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the renal denervation devices market by increasing costs of imported catheters, generators, ablation components, imaging accessories, and precision electronic parts used in minimally invasive systems. Hospitals and cardiovascular centers in North America and Europe are most affected due to dependence on imported medical devices, while Asia-Pacific faces pricing pressure on advanced interventional equipment. These tariffs are raising procedure costs and influencing procurement decisions. However, they are also encouraging localized manufacturing, regional supplier partnerships, and greater investment in domestic production of cardiovascular intervention devices.
The renal denervation devices market research report is one of a series of new reports that provides renal denervation devices market statistics, including renal denervation devices industry global market size, regional shares, competitors with a renal denervation devices market share, detailed renal denervation devices market segments, market trends and opportunities, and any further data you may need to thrive in the renal denervation devices industry. This renal denervation devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Renal denervation devices represent minimally invasive medical solutions designed for the treatment of resistant hypertension cases unresponsive to conventional interventions. These devices involve the insertion of a catheter into the renal arteries, employing radiofrequency energy to ablate sympathetic nerves within the vessel walls. This process enhances blood flow to the kidneys.
Key products in the renal denervation devices market include the Simplicity Renal Denervation System, EnligHTN, Vessix Renal Denervation System, Iberis Renal Sympathetic Denervation System, Paradise Renal Denervation System, and others. The Simplicity Renal Denervation System, for instance, utilizes a catheter and generator to deliver radiofrequency energy to the renal nerves. Various technologies, such as radiofrequency ablation, ultrasound energy-based RDN, brachytherapy, chemical ablation, and others, are employed by these devices. Target end-users include hospitals, cardiovascular research centers, and other medical facilities.
The renal denervation devices market consists of sales of products including a single electrode, multi-electrode, irrigated catheter, and others. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Renal Denervation Devices Market Characteristics
3. Renal Denervation Devices Market Supply Chain Analysis
4. Global Renal Denervation Devices Market Trends and Strategies
5. Renal Denervation Devices Market Analysis of End Use Industries
7. Global Renal Denervation Devices Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Renal Denervation Devices Total Addressable Market (TAM) Analysis for the Market
9. Renal Denervation Devices Market Segmentation
10. Renal Denervation Devices Market Regional and Country Analysis
11. Asia-Pacific Renal Denervation Devices Market
12. China Renal Denervation Devices Market
13. India Renal Denervation Devices Market
14. Japan Renal Denervation Devices Market
15. Australia Renal Denervation Devices Market
16. Indonesia Renal Denervation Devices Market
17. South Korea Renal Denervation Devices Market
18. Taiwan Renal Denervation Devices Market
19. South East Asia Renal Denervation Devices Market
20. Western Europe Renal Denervation Devices Market
21. UK Renal Denervation Devices Market
22. Germany Renal Denervation Devices Market
23. France Renal Denervation Devices Market
24. Italy Renal Denervation Devices Market
25. Spain Renal Denervation Devices Market
26. Eastern Europe Renal Denervation Devices Market
27. Russia Renal Denervation Devices Market
28. North America Renal Denervation Devices Market
29. USA Renal Denervation Devices Market
30. Canada Renal Denervation Devices Market
31. South America Renal Denervation Devices Market
32. Brazil Renal Denervation Devices Market
33. Middle East Renal Denervation Devices Market
34. Africa Renal Denervation Devices Market
36. Renal Denervation Devices Market Competitive Landscape and Company Profiles
37. Renal Denervation Devices Market Other Major and Innovative Companies
40. Renal Denervation Devices Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Renal Denervation Devices Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses renal denervation devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for renal denervation devices? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The renal denervation devices market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product: Simplicity Renal Denervation System; EnligHTN; Vessix Renal Denervation System; Iberis Renal Sympathetic Denervation System; Paradise Renal Denervation System; Other Products2) By Technology: Radio Frequency Ablation; Ultrasound Energy-Based RDN; Other Technologies
3) By End-Users: Hospitals; Cardiovascular research centre; Other End-Users
Subsegments:
1) By Simplicity Renal Denervation System: Catheter System; Accessories2) By EnligHTN: Catheter System; Generator; Accessories
3) By Vessix Renal Denervation System: Balloon Catheter; Generator; Accessories
4) By Iberis Renal Sympathetic Denervation System: Catheter System; Accessories
5) By Paradise Renal Denervation System: Catheter System; Accessories
6) By Other Products: Emerging Technologies; Alternative Devices
Companies Mentioned: Medtronic PLC; ReCor Medical Inc.; Boston Scientific Corporation; Abbott Laboratories; Cordis Corporation; Terumo Corporation; Kona Medical Inc.; St. Jude Medical LLC; Johnson & Johnson; Symple Surgical Inc.; Cardiosonic Ltd.; Mercator MedSystems Inc.; Ablative Solutions Inc.; Renal Dynamics Ltd.; Vesalio LLC; Biotronik SE & Co. KG; Cook Medical LLC; Hansen Medical Inc.; Merit Medical Systems Inc.; AngioDynamics Inc.; Covidien Ltd.; Volcano Corporation
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Renal Denervation Devices market report include:- Medtronic PLC
- ReCor Medical Inc.
- Boston Scientific Corporation
- Abbott Laboratories
- Cordis Corporation
- Terumo Corporation
- Kona Medical Inc.
- St. Jude Medical LLC
- Johnson & Johnson
- Symple Surgical Inc.
- Cardiosonic Ltd.
- Mercator MedSystems Inc.
- Ablative Solutions Inc.
- Renal Dynamics Ltd.
- Vesalio LLC
- Biotronik SE & Co. KG
- Cook Medical LLC
- Hansen Medical Inc.
- Merit Medical Systems Inc.
- AngioDynamics Inc.
- Covidien Ltd.
- Volcano Corporation
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 0.98 Billion |
| Forecasted Market Value ( USD | $ 3.01 Billion |
| Compound Annual Growth Rate | 32.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 23 |
